期刊文献+

阿米福韦类似物及其前药的设计、合成与生物活性 被引量:2

Design,synthesis and biological activity of prodrugs of alamifovir analogs
原文传递
导出
摘要 目的对新型抗乙肝药物阿米福韦进行结构改造,设计合成新的前药。方法以2-氯乙醇为原料,经氯甲基化、取代、缩合、烃化、水解、缩合得到目标产物。结果合成了11个新结构化合物,并经1H-NMR、13C-NMR、MS确证结构。体外抗乙肝病毒活性测试结果显示,阿米福韦异丙基碳酸酯的抗病毒活性显著提高,为阿米福韦的100倍。结论阿米福韦碳酸酯能够更好的释放活性药物,提高抗病毒活性。 Aim To design and synthesize new alamifovir analogs prodrugs.Methods The target compounds were synthesized via chloromethylation,substitution,condensation,alkylation,hydrolization,condensation using 2-chloroethanol as starting material.Results 11 New compounds were synthesized and characterized with 1H-NMR,13C-NMR and MS.In vitro anti-HBV activity evaluation revealed that new alamifovir prodrug 1a is about 100 times more potent than alamifovir.Conclusion The anti-HBV activity of the new prodrug of alamifovir derivatives can be improved by releasing the active molecule more efficiently.
出处 《中国药物化学杂志》 CAS CSCD 2010年第6期484-489,共6页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(30400566) 国家十一五"重大新药创制"项目(2009ZX09103-020)
关键词 阿米福韦 抗乙肝 碳酸酯前药 合成 alamifovir anti-HBV carbonate prodrug synthesis
  • 相关文献

参考文献5

  • 1FISCHER K P, GUTFREUND K S, TYRRELL D L.Lamivudine resistance in hepatitis B: mechanisms and clinical implications [ J ]. Drug Resist Update, 2001,4 (2) :118 - 135.
  • 2CLARK C, GEORG G, IKARI W, et al. Clinical phar- macokinetics of alamifovir and its metabolites antivi- crob agents chemother [ J ]. 2005,49 ( 5 ) : 1813 - 1822.
  • 3ONO-NITA S K, KATO N, SHIRATORI Y, et al. Novel nucleoside analogue MCC-478 ( LY582563 ) is effective against wild-type or lamivudine-resistant hepatitis B virus[ J]. Antimicrob Agents Chemother, 2002,46:2602 - 2605.
  • 4KAMIYA N, KUBOTA A, IWASE Y, et al. Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus[ J]. Antirnicrob Agents Chemoth- er,2002,46 (9) : 2872.
  • 5KOUICHI S, HIDEAKI T, NAOKO U, et al. 2-Ami- no-6-arylthio-9- [ 2- ( phosphonomethoxy ) ethyl ] -pu- rine bis(2,2,2-trifluoroethyl) esters as novel HBV- specific antiviral reagents [ J ]. J Med Chem, 2002, 45:3138 - 3142.

同被引文献13

  • 1Xiao Zhong Fu,Sai Hong Jiang,Jian Xin,Yu She Yang,RU Yun Ji.Design, synthesis and in vitro evaluation of L-amino acid esters prodrugs of acyclic nucleoside phosphonates as anti-HBV agent[J].Chinese Chemical Letters,2007,18(7):817-819. 被引量:1
  • 2LAVANCHY D. Hepatit is B virus epidemiology, disease hurden, treatment and current and emerging prevention and control meas- ures[J]. J ViraIHepat, 2004, 11(2) :97 -107.
  • 3DE CLERCQ E. Strategies in the design of antiviral drugs[J]. Nat Rev Drug Discov, 2002, 1 (1) :13 -25.
  • 4ZOULIM F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance [ J ]. Semin Liver Dis, 2002, 22(Suppl 1): 23 -31.
  • 5SEKIYA K, TAKASHIMA H, UEDA N, et al. 2-Amino-6-aryl- thio-9- [ 2- ( phosphonomethoxy ) ethyl ] purine bis ( 2,2,2-trifla- oroethyl) esters as novel HBY-specific antiviral reagents[ J]. J Med Chem, 2002, 45 ( 14 ) :3138 - 3142.
  • 6CHOI JT, H WANG JR. Novel phosphonate nucleosides as anti- viral agents[J]. Drugs Future, 2004, 29(2) :163 -177.
  • 7FISCHER KP, GUTFREUND KS, TYRRELL DL. Lamivudine resistance in hepatitis B: mechanisms and clinical in plications [J]. Drug Resist Update, 2001, 4(2): 118-135.
  • 8ONO-NITA SK, KATO N, SHIRATORI Y, et al. Novel nucleo-side analogue MCC-478 (LY582563) is effective against wild- type or lain ivudine resistant hepatitis B virus[ J].Antirnicrob A- gents Chemother, 2002, 46 ( 8 ) :2602 - 2605.
  • 9KAMIYA N, KUBOTA A, IWASE Y, et al. Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus [ J]. Antimicrob Agents Chemother, 2002, 46 (9) :2872 - 2877.
  • 10李庶心,匡先照,肖文松,张奉学,赵砚瑾,邓晓东,孙小梅.新型核苷膦酸酯类化合物的合成及其抗乙肝病毒活性研究[J].中国药物化学杂志,2007,17(6):344-347. 被引量:1

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部